PW59: Improving Lifespan and Healthspan with Menopausal Hormone Therapy (MHT) (self study) Price: $105.00 Status: Available
Pharmacy Webinar 59
CNDA Members: Use Your Coupon Code (member) At Checkout
Originally presented June 2025
CMEs 2 pharmacy CEs
Dr. Kelly Ruef, ND
Menopausal hormone therapy (MHT) is a hot topic right now, and for good reason – it has been shown to improve a number of postmenopausal ailments and may even help to prevent bone loss, heart disease, cognitive decline, and dementia in some women. This presentation will not only delve into the evidence behind these claims but will also discuss the importance of choosing the right dose and route of administration, monitoring MHT, and assessing hormone metabolism patterns. Research has shown that estradiol (E2) preparations do not increase patients’ serum E2 levels to the same degree, thus it may be advantageous to monitor E2 therapy to ensure a patient is within the therapeutic range and not being under- or over- dosed. Additionally, physicians can monitor hormone metabolism to decrease the rare risk of breast cancer associated with estrogen therapy and lower potential side effects of MHT.
GOALS AND OBJECTIVES
● Understand the evidence showing MHT improves VMS, GSM, VVA, incontinence, UTIs, sleep disturbances, and may prevent bone loss, heart disease, cognitive decline, and dementia.
● Recognize that a patient’s medical history, age and years out from menopause can affect the benefit-risk balance of MHT.
● Understand that every patient is unique and may not respond to (absorb) MHT similarly to the average patient, thus it is important to monitor circulating estradiol levels to ensure optimal patient outcomes.
● Recognize which laboratory methods and tests to use when monitoring EPT.
● Understand how monitoring estrogen metabolites in the urine may help to reduce the rare breast cancer risk associated with MHT and lower potential side effects of MHT.
